|
In-Person Research & Development Day
Date: Wednesday, December 14, 2022
Location: Lotte New York Palace Hotel
8:30 AM ET – Breakfast/Check-In
9:00 AM ET – 11:00 AM ET - Presentations
Hosted by Y-mAbs Therapeutics (NASDAQ: YMAB)
| |
|
Y-mAbs Therapeutics invites you to their annual R&D Day, featuring presentations of the company, its clinical development and advanced product pipeline.
Company Presenters:
-
Thomas Gad (Founder, President, and Interim Chief Executive Officer at Y-mAbs Therapeutics) will give a corporate presentation.
-
Steen Lisby, M.D., DMSc, (SVP, Chief Scientific Officer at Y-mAbs Therapeutics) will present pipeline news and an overview of the investigational SADA technology platform (Liquid RadiationTM).
-
Vignesh Rajah, MBBS, DCH, MRCP (UK) MBA, (SVP, Chief Medical Officer at Y-mAbs Therapeutics), will present an update on the potential DANYELZA® (naxitamab-gqgk) label expansion into osteosarcoma, which is investigational, and a multicenter Phase 2 trial in patients with newly diagnosed high-risk neuroblastoma.
A question-and-answer session will follow the formal presentations.
| |
|
Registration Information
You are required to register in advance for this event. The event will also be webcasted and a replay will be available here.
| |  |
|
Q&A Information
If you would like to ask a question during the live Q&A, please submit your request to [email protected].
| |
|
Thomas Gad
Thomas Gad is Founder, President, Interim Chief Executive Officer and Head of Business Development and Strategy. Inspired by his daughter’s transformational and challenging journey through years of high-risk neuroblastoma treatment and her experience receiving breakthrough immunotherapy at Memorial Sloan Kettering Cancer Center to overcome the cancer, Mr. Gad founded Y-mAbs Therapeutics and secured seed capital. Mr. Gad has more than 12 years of experience in the pharmaceutical industry, including business development, senior management, financing, and licensing negotiations. Mr. Gad has a Bachelor of Science degree in Business Administration from Pepperdine University, California, US.
| |
|
Steen Lisby, MD, DMSc
Steen Lisby, MD, DMSc, serves as SVP, Chief Scientific Officer. Dr. Lisby received his MD and his Doctorate of Medical Science from the University of Copenhagen, Denmark, and has extensive scientific and clinical experience. He is the author of over 50 scientific, peer-reviewed publications in the field of clinical research. Dr. Lisby previously worked at GlaxoSmithKline plc and Genmab A/S.
| |
|
Vignesh Rajah, MBBS, DCH, MRCP(UK), MBA
Vignesh Rajah, MBBS, DCH, MRCP(UK), MBA, serves as SVP, Chief Medical Officer. Dr Rajah qualified as physician at the University of London, and has 10 years’ experience in hospital practice, specializing in Internal Medicine and Pediatric Critical Care in the UK. Dr. Rajah has worked at Sanofi, Wyeth and GSK, covering multiple therapeutic areas such as Oncology, Vaccines, Immunology and Respiratory.
| |
|
About DANYELZA® (naxitamab-gqgk)
DANYELZA® (naxitamab-gqgk) is indicated, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication was approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory trial. DANYELZA® includes a Boxed Warning for serious infusion-related reactions, such as cardiac arrest and anaphylaxis, and neurotoxicity, such as severe neuropathic pain and transverse myelitis. See full Prescribing Information for complete Boxed Warning and other important safety information.
| |
Copyright © 2021 LifeSci Advisors, LLC, All rights reserved.
This message contains confidential and proprietary information and is intended only for the individual named. If you are not the named addressee you should not disseminate, distribute or copy this e-mail. Please notify the sender immediately by e-mail if you have received this email by mistake and delete this email from your system. All market prices, data and other information contained in this email are not warranted as to completeness or accuracy and are subject to change without notice. Any comments or statements made herein do not necessarily reflect the views of LifeSci Advisors, LLC, its affiliates, subsidiaries or agents. The message is not intended as an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Before opening any attachments please check them for viruses and defects.
| | | | | |
